Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) Stock Information | RedChip

Enanta Pharmaceuticals Inc. (NASDAQ: ENTA)


$6.0900
-0.0100 ( +0.16% ) 241.8K

Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Market Data


Open


$6.0900

Previous close


$6.1000

Volume


241.8K

Market cap


$129.29M

Day range


$5.7300 - $6.2250

52 week range


$5.7000 - $17.8000

SEC Filings


Form Type Description Pages Date
4 Insider transactions 1 Feb 14, 2024
4 Insider transactions 1 Feb 14, 2024
4 Insider transactions 1 Feb 14, 2024
4 Insider transactions 1 Feb 14, 2024
4 Insider transactions 1 Feb 14, 2024
10-q Quarterly Reports 60 Feb 08, 2024
8-k 8K-related 14 Feb 07, 2024
ars Annual reports 1 Jan 26, 2024
def Proxies and info statements 63 Jan 26, 2024
8-k 8K-related 12 Dec 26, 2023

Latest News